The Mirasol Evaluation Program:: Use of Mirasol Pathogen Reduction Technology for platelets in routine clinical practice

被引：0
|
作者：
Cock, P. D. [1 ]
Vaquero, M.
Garcia, R.
Marceno, R.
Fusco, G. D.
Freitas, A. [1 ]
Goodrich, R.
机构：
[1] Gambro BCT, Zaventem, Belgium
来源：
TRANSFUSION | 2008年 / 48卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：156A / 156A
页数：1
相关论文
共 50 条
  • [31] Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice
    Caudrillier, A.
    Mallavia-Onaindia, B.
    Rouse, L.
    Marschner, S.
    Looney, M. R.
    [J]. TRANSFUSION, 2013, 53 : 134A - 134A
  • [32] Pathogen reduction technology (Mirasol®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS
    Janetzko, K.
    Hinz, K.
    Marschner, S.
    Goodrich, R.
    Klueter, H.
    [J]. VOX SANGUINIS, 2009, 97 (03) : 234 - 239
  • [33] Evaluation of pathogen reduction in whole blood with the Mirasol® system for whole blood
    Doane, S.
    Reddy, H.
    Fitzpatrick, C.
    Keil, S.
    Goodrich, R.
    [J]. TRANSFUSION, 2008, 48 (02) : 87A - 87A
  • [34] Protein quality in Mirasol Pathogen Reduction Technology treated apheresis derived FFP
    Smith, James W.
    Rock, G.
    Buytaert-Hoefen, Kimberley
    Hendrix, B.
    Bihm, D.
    Goodrich, R.
    [J]. TRANSFUSION, 2008, 48 (02) : 146A - 146A
  • [35] Evaluation of Pathogen Reduction Technologies, Phase 1: In Vitro Quality Markers of Mirasol-Treated Platelets.
    de Grandmont, Marie Joelle
    Dussault, Nathalie
    Ducas, Eric
    Landry, Patricia
    Laforce-Lavoie, Audrey
    Nolin, MArie-Eve
    Cayer, Marie-Pierre
    Cloutier, Marc
    Drouin, Francois
    Brouard, Danny
    [J]. TRANSFUSION, 2017, 57 : 84A - 85A
  • [36] Clinical evaluation of mirasol PRT treated apheresis platelets in thrombocytopenic patients
    Goodrich, R.
    Follea, G.
    Roberts, T.
    [J]. TRANSFUSION, 2008, 48 (02) : 20A - 20A
  • [37] Hematocompatibility of red blood cells treated with the mirasol pathogen reduction technology system
    Reddy, H. L.
    Buytaert-Hoefen, K. A.
    Doane, S. K.
    Fitzpatrick, C. N.
    Marschner, S.
    Goodrich, R. P.
    [J]. TRANSFUSION, 2007, 47 (03) : 95A - 95A
  • [38] In-vitro function of platelets treated with MIRASOL for pathogen reduction compared with control and irradiated units
    Picker, S. M.
    Steisel, A.
    Gathof, B. S.
    [J]. TRANSFUSION, 2007, 47 (03) : 78A - 79A
  • [39] QUALITY CONTROL OF FIBRINOGEN CONCENTRATE FROM PLASMA TREATED IN MIRASOL® PATHOGEN REDUCTION TECHNOLOGY
    Lachert, E.
    Kubis, J.
    Antoniewicz-Papis, J.
    Rosiek, A.
    Potocka, E.
    Poglod, R.
    Letowska, M.
    [J]. VOX SANGUINIS, 2013, 105 : 154 - 154
  • [40] Routine Use of Mirasol® Treated Blood Componenets in Warsaw
    Piotrowski, D.
    Przybylska-Baluta, Z.
    Leleno, M.
    Uszynska, A.
    Cardoso, M.
    [J]. TRANSFUSION, 2011, 51 : 43A - 43A
12345